Clearside Biomedical Aktie (A2ALP6

Was macht Clearside Biomedical?

Unternehmensprofil

Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Chart der Clearside Biomedical Aktie

Charttool öffnen

Aktuelle Nachrichten zu Clearside Biomedical

Weitere Nachrichten

Das berichten andere über Clearside Biomedical

Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates

Clearside Biomedical (CLSD) delivered earnings and revenue surprises of -70.15% and -23.57%, respectively, for the quarter ended September 2025. Do the numbers hold clues...

Clearside Biomedical stock falls after announcing strategic alternatives exploration By Investing.com

Clearside Biomedical stock falls after announcing strategic alternatives exploration

Clearside Biomedical to explore strategic alternatives amid cash concerns By Investing.com

Clearside Biomedical to explore strategic alternatives amid cash concerns

Clearside Biomedical (CLSD) Upgraded to Buy: Heres What You Should Know

Clearside Biomedical (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).